Akeso's ivonescimab reduces death risk by 34% in phase three lung cancer trial, the first Chinese drug selected for ASCO's plenary in 61 years, targeting a $20B market.

PD-(L)1×VEGF bispecifics have emerged as a closely watched new class in immuno-oncology, with multiple candidates advancing ...

VEGF biosimilar has moved closer to European approval for several vision-threatening retinal diseases, including choroidal neovascularization.

A new research published in the journal of BMC Oral Health showed that the use of injectable platelet-rich fibrin (iPRF) may ...

First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with ...

Pharming’s Joenja receives European marketing authorization for the treatment of activated PI3K delta syndrome: Leiden, the Netherlands Tuesday, May 26, 2026, 13:00 Hrs [IST] Ph ...

Summit Therapeutics Inc. today presented new results from the AK112-206 trial (NCT05382442), a global, open-label, multicenter Phase II study in first-line metastatic colorectal cancer (mCRC) ...

Dr. Emmalyn Pratt, ND   Subheadline Two fertility case reports exploring the potential role of ovarian platelet-rich plasma ...

Dual PD-1 and VEGF blockade with ivonescimab is positioned to augment chemo-immunotherapy efficacy in advanced squamous NSCLC, addressing a historically poor-prognosis population with limited advances ...

Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.

Common medications used to treat anemia may also slow down cancer cell growth, according to new research from Finland. Researchers from the University of Oulu and the University of Eastern Finland ...